Reports Q4 revenue $3.5M, consensus $870K. Expects its cash, cash equivalents, and short-term investments as of December 31, 2022, plus gross proceeds of $50.0M from March 2023 private placement financing to fund operations into the middle of 2025. "Following our strategic financing, we believe we are securely positioned to advance etripamil for paroxysmal supraventricular tachycardia through the approval process and into launch," said CEO Joseph Oliveto. "With FDA guidance in hand and our Phase 3 studies complete, we are one step closer to achieving our goal of establishing etripamil as the first fast-acting, patient-administered treatment for PSVT. We remain on track for a New Drug Application submission in Q3."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MIST:
